John Overdeck’s Axsome Therapeutics AXSM Stock Holding History

John Overdeck’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	+4,400	New	+$954K	﹤0.01%	3565

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

John Overdeck's AXSM Position: Q2 2026 in Review

John Overdeck increased its Axsome Therapeutics (AXSM) stake by 107% in Q2 2026, buying an estimated $75.2M and bringing the position to 669,478 shares worth $164M. The position accounts for 0.12% of the portfolio, ranked #187.

John Overdeck first reported a position in AXSM in Q4 2020 and has held it in 11 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

John Overdeck held 669,478 shares of Axsome Therapeutics worth $164M as of Q2 2026.
John Overdeck bought 346,700 Axsome Therapeutics shares in Q2 2026, an estimated $75.2M.
Axsome Therapeutics made up 0.12% of John Overdeck's portfolio in Q2 2026, its #187 holding.
John Overdeck first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 11 quarters since.
502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.